CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 29, 2026, 1:21 PM EST
CNBX Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Cash & Equivalents | 0.01 | 0.02 | 0.03 | 0.13 | 0.12 | 1.39 |
Cash & Short-Term Investments | 0.01 | 0.02 | 0.03 | 0.13 | 0.12 | 1.39 |
Cash Growth | -30.49% | -42.80% | -79.63% | 10.37% | -91.52% | 78.30% |
Prepaid Expenses | 0 | 0 | 0 | 0.09 | 0.08 | 0.2 |
Total Current Assets | 0.01 | 0.02 | 0.03 | 0.22 | 0.2 | 1.59 |
Property, Plant & Equipment | - | - | - | 0.27 | 0.44 | 0.64 |
Long-Term Investments | - | - | - | - | 0.18 | 0.85 |
Total Assets | 0.01 | 0.02 | 0.03 | 0.5 | 0.81 | 3.08 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Accounts Payable | 0.05 | 0.05 | 0.04 | 0.34 | 0.46 | 0.18 |
Accrued Expenses | 1.22 | 1.04 | 0.93 | 0.61 | - | - |
Short-Term Debt | 1.17 | 1.2 | 1.3 | 1.34 | 1.76 | 0.87 |
Other Current Liabilities | 0.24 | 0.22 | 0.24 | 0.22 | 0.22 | 0.22 |
Total Current Liabilities | 2.67 | 2.51 | 2.51 | 2.52 | 2.44 | 1.27 |
Other Long-Term Liabilities | - | - | - | - | 0 | - |
Total Liabilities | 2.67 | 2.51 | 2.51 | 2.52 | 2.44 | 1.27 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Common Stock | 0.15 | 0.06 | 0 | 0 | 0 | 0.01 |
Additional Paid-In Capital | 22.77 | 22.72 | 22.47 | 22.24 | 18.03 | 17.06 |
Retained Earnings | -25.58 | -25.27 | -24.95 | -24.26 | -20.55 | -16.83 |
Comprehensive Income & Other | - | - | - | - | 0.88 | 1.55 |
Shareholders' Equity | -2.66 | -2.5 | -2.48 | -2.02 | -1.63 | 1.81 |
Total Liabilities & Equity | 0.01 | 0.02 | 0.03 | 0.5 | 0.81 | 3.08 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Total Debt | 1.17 | 1.2 | 1.3 | 1.34 | 1.76 | 0.87 |
Net Cash (Debt) | -1.16 | -1.18 | -1.27 | -1.21 | -1.64 | 0.51 |
Net Cash Growth | - | - | - | - | - | -33.83% |
Net Cash Per Share | -0.00 | -0.01 | -0.04 | -0.14 | -1.34 | 0.45 |
Filing Date Shares Outstanding | 1,606 | 753.2 | 31.11 | 28.31 | 1.26 | 1.24 |
Total Common Shares Outstanding | 1,476 | 553.96 | 31.11 | 22.61 | 1.26 | 1.24 |
Working Capital | -2.66 | -2.5 | -2.48 | -2.29 | -2.25 | 0.32 |
Book Value Per Share | -0.00 | -0.00 | -0.08 | -0.09 | -1.30 | 1.46 |
Tangible Book Value | -2.66 | -2.5 | -2.48 | -2.02 | -1.63 | 1.81 |
Tangible Book Value Per Share | -0.00 | -0.00 | -0.08 | -0.09 | -1.30 | 1.46 |